He Chi Shi

Researchers are evaluating the protective effects, safety, and immune response of an 11-valent recombinant human papillomavirus HPV vaccine in Chinese women aged 18 to 45 years. This Phase III clinical trial involves 13,500 women divided into three age groups to assess the vaccines ability to prevent HPV infections and related cervical lesions. Participants are randomized into experimental and placebo groups to compare outcomes. The trial administers three doses of either the HPV vaccine or a placebo via intramuscular injections into the upper arm deltoid muscle, scheduled at 0, 2, and 6 months. The study uses a double-blind design to ensure unbiased results. The vaccine targets multiple HPV types associated with cervical cancer and related conditions. Participants will undergo follow-up visits including gynecological examinations, pregnancy testing, and monitoring for adverse events. Researchers will measure the incidence of cervical intraepithelial neoplasia CIN and HPV-related lesions, as well as antibody responses at multiple time points after vaccination. The trial includes long-term monitoring up to six years to evaluate vaccine safety and effectiveness.

Researchers are evaluating the use of Tislelizumab BGB-A317, an anti-PD-1 monoclonal antibody, in adults with previously treated locally advanced unresectable or metastatic solid tumors that are mismatch repair deficient dMMR or microsatellite instability-high MSI-H. This Phase 2, single-arm, multi-center, open-label study aims to assess the efficacy and safety of Tislelizumab as monotherapy in this patient population. Participants will receive Tislelizumab as the study treatment. The study does not include a comparison group and involves ongoing treatment with Tislelizumab under medical supervision. The treatment period and assessment extend up to two years to evaluate response and survival outcomes. Throughout the study, participants will undergo regular evaluations including imaging and clinical assessments to measure tumor response using RECIST version 1.1 criteria. Researchers will monitor progression-free survival, overall survival, disease control rate, duration and time to response, as well as safety and tolerability through adverse event tracking. Participation may last up to two years, with ongoing safety monitoring during this time.